ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Contrast-enhanced mammography based quantitative and qualitative feature analysis across different breast cancer molecular subtypes.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo investigate the imaging manifestations of different molecular subtypes of breast cancer (BC) by contrast enhanced mammography (CEM).
methodsFrom April 2019 to January 2022, 183 BC patients with suspected malignant mass underwent CEM examination were included. The differences in imaging features among different subtypes of breast cancer, as well as the detailed correlations, were determined using chi-square test, cross-contingency table method, and multivariate logistic analysis.
resultsThere were significant differences among four BC molecular subtypes in terms of lesion size (C = 0.306, P = 0.003), morphology (C = 0.296, P = 0.000), enhancement pattern (C = 0.461, P = 0.000), time-gray curve type (C = 0.296, P = 0.000), and the ration of presence of microcalcification (C = 0.246, P = 0.006). No significant difference were found in age, lesion margin, enhancement degree and background parenchyma enhancement of BC among different tumor subtypes. Luminal A group was mostly characterized with lesion size ≤ 2 cm (63%), and showed high ratio of heterogeneous enhancement (90.0%). Luminal B type was more featured by mass-appearance (74.6%), circular margin (40.9%), and plateau curve (45.8%). BC with HER-2 overexpression exhibited high proportion of non-mass lesions (66.7%). Triple-negative BC was more common with mass-type lesion (91.3%), oval shape (47.6%) and rim enhancement (66.7%).
conclusionIn summary, the imaging features of lesion size, morphology, enhancement patterns and perfusion change on CEM images in BC vary among different molecular subtypes., aiding in preliminary prediction and analysis of the molecular subtypes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.